213 related articles for article (PubMed ID: 16817233)
21. Hydrogen Bond Dynamic Propensity Studies for Protein Binding and Drug Design.
Menéndez CA; Accordino SR; Gerbino DC; Appignanesi GA
PLoS One; 2016; 11(10):e0165767. PubMed ID: 27792778
[TBL] [Abstract][Full Text] [Related]
22. Characterizing the conformational landscape of MDM2-binding p53 peptides using Molecular Dynamics simulations.
Yadahalli S; Li J; Lane DP; Gosavi S; Verma CS
Sci Rep; 2017 Nov; 7(1):15600. PubMed ID: 29142290
[TBL] [Abstract][Full Text] [Related]
23. Molecular interaction fields and 3D-QSAR studies of p53-MDM2 inhibitors suggest additional features of ligand-target interaction.
Dezi C; Carotti A; Magnani M; Baroni M; Padova A; Cruciani G; Macchiarulo A; Pellicciari R
J Chem Inf Model; 2010 Aug; 50(8):1451-65. PubMed ID: 20726601
[TBL] [Abstract][Full Text] [Related]
24. Molecular dynamics studies on Mdm2 complexes: an analysis of the inhibitor influence.
Almerico AM; Tutone M; Pantano L; Lauria A
Biochem Biophys Res Commun; 2012 Jul; 424(2):341-7. PubMed ID: 22771796
[TBL] [Abstract][Full Text] [Related]
25. Simulating molecular mechanisms of the MDM2-mediated regulatory interactions: a conformational selection model of the MDM2 lid dynamics.
Verkhivker GM
PLoS One; 2012; 7(7):e40897. PubMed ID: 22815859
[TBL] [Abstract][Full Text] [Related]
26. The molecular dynamics of MDM2.
Nicholson J; Hupp TR
Cell Cycle; 2010 May; 9(10):1878-81. PubMed ID: 20436290
[TBL] [Abstract][Full Text] [Related]
27. Molecular dynamics simulations studies and free energy analysis on inhibitors of MDM2-p53 interaction.
Niu RJ; Zheng QC; Zhang JL; Zhang HX
J Mol Graph Model; 2013 Nov; 46():132-9. PubMed ID: 24211465
[TBL] [Abstract][Full Text] [Related]
28. Identification of antipsychotic drug fluspirilene as a potential p53-MDM2 inhibitor: a combined computational and experimental study.
Patil SP; Pacitti MF; Gilroy KS; Ruggiero JC; Griffin JD; Butera JJ; Notarfrancesco JM; Tran S; Stoddart JW
J Comput Aided Mol Des; 2015 Feb; 29(2):155-63. PubMed ID: 25377899
[TBL] [Abstract][Full Text] [Related]
29. Design, Synthesis and Evaluation of 2,5-Diketopiperazines as Inhibitors of the MDM2-p53 Interaction.
Pettersson M; Quant M; Min J; Iconaru L; Kriwacki RW; Waddell MB; Guy RK; Luthman K; Grøtli M
PLoS One; 2015; 10(10):e0137867. PubMed ID: 26427060
[TBL] [Abstract][Full Text] [Related]
30. Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy.
Lu Y; Nikolovska-Coleska Z; Fang X; Gao W; Shangary S; Qiu S; Qin D; Wang S
J Med Chem; 2006 Jun; 49(13):3759-62. PubMed ID: 16789731
[TBL] [Abstract][Full Text] [Related]
31. Bridging Microscopic and Macroscopic Mechanisms of p53-MDM2 Binding with Kinetic Network Models.
Zhou G; Pantelopulos GA; Mukherjee S; Voelz VA
Biophys J; 2017 Aug; 113(4):785-793. PubMed ID: 28834715
[TBL] [Abstract][Full Text] [Related]
32. Probing the origin of structural stability of single and double stapled p53 peptide analogs bound to MDM2.
Guo Z; Streu K; Krilov G; Mohanty U
Chem Biol Drug Des; 2014 Jun; 83(6):631-42. PubMed ID: 24418072
[TBL] [Abstract][Full Text] [Related]
33. Chemical states of the N-terminal "lid" of MDM2 regulate p53 binding: simulations reveal complexities of modulation.
Dastidar SG; Raghunathan D; Nicholson J; Hupp TR; Lane DP; Verma CS
Cell Cycle; 2011 Jan; 10(1):82-9. PubMed ID: 21191186
[TBL] [Abstract][Full Text] [Related]
34. Computational analysis of spiro-oxindole inhibitors of the MDM2-p53 interaction: insights and selection of novel inhibitors.
Huang W; Cai L; Chen C; Xie X; Zhao Q; Zhao X; Zhou HY; Han B; Peng C
J Biomol Struct Dyn; 2016; 34(2):341-51. PubMed ID: 25808617
[TBL] [Abstract][Full Text] [Related]
35. Structure of human MDM2 complexed with RPL11 reveals the molecular basis of p53 activation.
Zheng J; Lang Y; Zhang Q; Cui D; Sun H; Jiang L; Chen Z; Zhang R; Gao Y; Tian W; Wu W; Tang J; Chen Z
Genes Dev; 2015 Jul; 29(14):1524-34. PubMed ID: 26220995
[TBL] [Abstract][Full Text] [Related]
36. Efficient Atomistic Simulation of Pathways and Calculation of Rate Constants for a Protein-Peptide Binding Process: Application to the MDM2 Protein and an Intrinsically Disordered p53 Peptide.
Zwier MC; Pratt AJ; Adelman JL; Kaus JW; Zuckerman DM; Chong LT
J Phys Chem Lett; 2016 Sep; 7(17):3440-5. PubMed ID: 27532687
[TBL] [Abstract][Full Text] [Related]
37. Why is F19Ap53 unable to bind MDM2? Simulations suggest crack propagation modulates binding.
Dastidar SG; Lane DP; Verma CS
Cell Cycle; 2012 Jun; 11(12):2239-47. PubMed ID: 22617389
[TBL] [Abstract][Full Text] [Related]
38. Impact of the K24N mutation on the transactivation domain of p53 and its binding to murine double-minute clone 2.
Zhan YA; Wu H; Powell AT; Daughdrill GW; Ytreberg FM
Proteins; 2013 Oct; 81(10):1738-47. PubMed ID: 23609977
[TBL] [Abstract][Full Text] [Related]
39. Molecular mechanism of the interaction between MDM2 and p53.
Schon O; Friedler A; Bycroft M; Freund SM; Fersht AR
J Mol Biol; 2002 Oct; 323(3):491-501. PubMed ID: 12381304
[TBL] [Abstract][Full Text] [Related]
40. Modulation of p53 binding to MDM2: computational studies reveal important roles of Tyr100.
Dastidar SG; Lane DP; Verma CS
BMC Bioinformatics; 2009 Dec; 10 Suppl 15(Suppl 15):S6. PubMed ID: 19958516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
